EUVIMEDEUVIMED entdecken
Crossref

Multitargeted Anti‐Inflammatory Agents: Novel Pyrazole and Pyrazolo[1,5‐ a ]Pyrimidine Carbonic Anhydrase and COX‐2 Inhibitors With Optimal In Vivo Efficacy and Low Toxicity

Mariam M Fakhry iD, Mohamed A Said, Andrea Ammara, Jalloul Bouajila, Claudiu T Supuran iD, Hatem A Abdel-Aziz, Sahar M Abou-Seri

Drug Development Research · 2026

DOI: 10.1002/ddr.70214 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Development Research, 2026. Verfasst von Mariam M Fakhry und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Egyptian Russian University, Badr City, Cairo, Egypt. Hauptthemen laut MEDLINE: Carbonic Anhydrase Inhibitors, Pyrazoles, Cyclooxygenase 2 Inhibitors, Pyrimidines. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 88 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In this study, three series of pyrazole and pyrazolo[1,5‐ a ]pyrimidine derivatives 6a‐f , 8a‐f , and 10a‐f were designed and synthesized in response to the global need to safe and potent anti‐inflammatory agents. A rational design strategy was employed to synthesize compounds that inhibit inflammation‐related carbonic anhydrase isoforms (II, IX, and XII) alongside achieving selective inhibition of cyclooxygenase‐2 (COX‐2). Remarkably, the sulfonamide derivatives 6f, 8d, and 10e displayed high activity as carbonic anhydrase inhibitors against isoforms II, IX and XII in addition to their potent and selective COX‐2 inhibition effect (IC 50 = 57–87 nM; SI = 175–100). Among them, the multitargeted inhibitor 10e (COX‐2, IC 50 = 57 nM; CA II, K i = 49.9 nM; CA IX, K i = 67.5 nM; CA XII, K i = 54.6 nM) was further evaluated in vivo and demonstrated strong dual anti‐inflammatory and analgesic properties, with a rapid onset of action within the first hour and sustained efficacy over 5 h. Toxicological studies revealed that compound 10e possessed a favorable safety profile, showing no significant adverse effects on liver, kidney, or cardiac functions and minimal ulcerogenic potential. Molecular docking studies further supported these findings by confirming key binding interactions with CA II, IX, XII, and COX‐2 active sites.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carbonic Anhydrase InhibitorsPyrazolesCyclooxygenase 2 InhibitorsPyrimidinesAnti-Inflammatory AgentsAnimalsMaleMolecular Docking SimulationRatsCyclooxygenase 2Carbonic AnhydrasesStructure-Activity RelationshipHumansEdema

Stichwörter der Autor:innen

COX‐2 inhibitoranti‐inflammatorycarbonic anhydrasepyrazolepyrazolopyrimidine

Substanzen

Carbonic Anhydrase InhibitorsPyrazolesCyclooxygenase 2 InhibitorsPyrimidinesCyclooxygenase 2Anti-Inflammatory AgentsCarbonic Anhydrasespyrazolo(1,5-a)pyrimidine

Autor:innen und Institutionen

  • Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Egyptian Russian University, Badr City, Cairo, Egypt.
  • Laboratoire de Génie Chimique, Université de Toulouse, Toulouse INP, CNRS, LGC, Toulouse, France.
  • Department of pharmaceutical chemistry, College of Pharmacy, University of Kut, Waist, Iraq.
  • Department of NEUROFARBA, Section of Pharmaceutical and Nutraceutical Sciences, University of Florence, Polo Scientifico, Firenze, Italy.
  • Department of Applied Organic Chemistry Department, National Research Center, Dokki, Cairo, Egypt.
  • Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Cairo University, Kasr El-Aini Street, Cairo, Egypt.

ORCID-Profile: Mariam M Fakhry, Claudiu T Supuran

Zitieren

APA

Fakhry, M. M., Said, M. A., Ammara, A., Bouajila, J., Supuran, C. T., Abdel-Aziz, H. A., & Abou-Seri, S. M. (2026). Multitargeted Anti‐Inflammatory Agents: Novel Pyrazole and Pyrazolo[1,5‐ a ]Pyrimidine Carbonic Anhydrase and COX‐2 Inhibitors With Optimal In Vivo Efficacy and Low Toxicity. Drug Development Research. https://doi.org/10.1002/ddr.70214

Vancouver

Fakhry MM, Said MA, Ammara A, Bouajila J, Supuran CT, Abdel-Aziz HA, et al. Multitargeted Anti‐Inflammatory Agents: Novel Pyrazole and Pyrazolo[1,5‐ a ]Pyrimidine Carbonic Anhydrase and COX‐2 Inhibitors With Optimal In Vivo Efficacy and Low Toxicity. Drug Development Research. 2026. doi:10.1002/ddr.70214

BibTeX
@article{Fakhry2026,
  author = {Fakhry, Mariam M and Said, Mohamed A and Ammara, Andrea and Bouajila, Jalloul and Supuran, Claudiu T and Abdel-Aziz, Hatem A and Abou-Seri, Sahar M},
  title = {Multitargeted Anti‐Inflammatory Agents: Novel Pyrazole and Pyrazolo[1,5‐ a ]Pyrimidine Carbonic Anhydrase and COX‐2 Inhibitors With Optimal In Vivo Efficacy and Low Toxicity},
  journal = {Drug Development Research},
  year = {2026},
  doi = {10.1002/ddr.70214}
}
Kostenlos starten →